RBV Capital is a dedicated life sciences venture capital fund established in 2014 investing into innovative biomedical projects globally 

At RBV Capital, we are building a diversified portfolio of early-stage breakthrough assets.

Our investment strategy focuses on innovative science addressing critical unmet medical needs, and relies on selecting strong management teams with a clear vision.

We are interested in biopharmaceuticals, biomedical technology and services, bioinformatics and healthcare IT, and medical device companies.

News

1
jul

IAG & eTheRNA Partner in Immunotherapy Development Effort

eTheRNA immunotherapies NV, a clinical-stage Belgian company developing mRNA based immunotherapies for the treatment of cancer and IAG, a bio-pharma expert imaging company announced today a a collaboration aimed at facilitating the clinical evaluation of immuno-therapies based on eTheRNA’s proprietary mRNA-based TriMix platform with the use of IAG’s cloud based software DYNAMIKA.

More